SUMMARY A group of seven young women with antiphospholipid antibodies, histories of recurrent fetal loss, and no live births is reported. Two patients had systemic lupus erythematosus, and the other five fulfilled criteria for the primary antiphospholipid syndrome. A false Venereal Disease Research Laboratory (VDRL) test was present in four of the patients, three had a previous episode of arterial or venous thrombosis, or both, and two had thrombocytopenia. Prednisone and acetylsalicylic acid were given, and monthly controls of lupus anticoagulant activity were carried out. The dose of acetylsalicylic acid was fixed while the dose of steroids was adjusted according to the degree of lupus anticoagulant activity. A fetal survival was obtained in 7/9 (78%) of the pregnancies. Three of the newborn infants had transitory lupus anticoagulant activity. A search for antiphospholipid antibodies should be carried out in patients with otherwise unexplained fetal losses, falsely positive VDRL tests, thrombosis, or thrombocytopenia as the treatment of such patients with prednisone and acetylsalicylic acid is highly effective.
The so-called lupus anticoagulant is an antibody (IgG or IgM) that prolongs phospholipid dependent coagulation tests by binding to epitopes on the phospholipid portion of prothrombinase. ' The lupus anticoagulant is characteristically found in patients with systemic lupus erythematosus but has also been observed in patients with other diseases, especially in those with the primary antiphospholipid syndrome,2 and in apparently normal people.3 Despite in vitro prolongation of the partial thromboplastin time by lupus anticoagulant, its presence, paradoxically, has been associated with increased tendency towards thromboembolic events and not with an increased bleeding tendency.4 5 In women the presence of this antibody has recently emerged as an important marker for recurrent first trimester spontaneous miscarriages as well as for second and early third trimester fetal death.8 Treatment with prednisone and acetylsalicylic acid has been advocated as a means of improving pregnancy outcome in these patients.6 7 
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COAGULATION ASSAYS
The APYTs returned to normal at different rates. In patients 3 and 6 normalisation took place after a month of treatment. In patients 2, 4, and 5 the APTI became normal after two months with doses of prednisone of 30 mg a day. In patient 7 we were unable to normalise the APTT despite a daily prednisone dose of 60 mg. In patients 3 and 6 we were unable to reduce the dose of prednisone to 10 mg a day, and in patients 2, 4, and 6 20-30 mg a day of prednisone were required. In patient No 1 we started the treatment at the 8th and 12th week of each of her two pregnancies. During her first pregnancy we followed the usual protocol, but in the second pregnancy we started with a dose of 40 mg a day of prednisone and the APTT was not normal by the time the fetus died. Anticardiolipin antibody concentrations decreased in all five patients, being positive at concentrations below 15 GPL or 6 MPL, but not disappearing completely.
FETAL SURVIVAL
Seven of nine pregnancies ended with normal live births. Both failures occurred in patient No 1, at the 14th and 16th week of pregnancy, and were accompanied by vaginal haemorrhage; the fetal death was recorded by ultrasonography. In both instances there was complete vaginal expulsion and the fetuses appeared macroscopically normal. The placentas were of normal height and appearance, and histologically there were vascular thrombotic lesions and infarctions in the two specimens from patient No 1. The APTT had not returned to normal by the time of these obstetric complications. All other pregnancies ended between the 32nd and 36th week with normal deliveries and with fetal weights ranging from 2500 to 3500 g. We could only study the placentas of three of them (Nos 5, 6, 7), which were normal. Apgar scores were normal, and no malformations or complications were seen in the newborns. Determinations of APTI and DTI were performed in three infants and were consistent with the presence of a circulating anticoagulant. Further examinations carried out at six months were normal.
The prednisone treatment produced Cushingoid features in these patients, except in patient No 7, who, paradoxically, was receiving the largest dose of steroids. Steroids were progressively tapered in the postpartum period while acetylsalicylic acid was discontinued abruptly. In patient No 6 the lupus anticoagulant could not be detected by the usual coagulation tests in the controls performed after the puerperium. Thrombotic complications in the postpartum period were not observed, which contrasted with the experience of several patients in previous pregnancies (Table 3 ).
Discussion
The presence of the lupus anticoagulant in women with or without systemic lupus erythematosus has been reported to be associated with a high incidence of first trimester spontaneous miscarriages and second and third trimester fetal deaths.7 8 1122 Measurement of anticardiolipin antibodies, alone or in conjunction with lupus anticoagulant determinations, has proved to be a good predictor of fetal distress or fetal death. 13 Currently, lupus anticoagulant and anticardiolipin antibodies are considered good markers of obstetric complications. Most patients with the lupus anticoagulant also have anticardiolipin antibodies, but some are only positive for one of the two antibodies.23 24 Both types of antiphospholipid antibody are useful as predictors of obstetric complications, though anticardiolipin antibodies seem to be more sensitive and easier to measure.13 19 20 25 In this series two patients were positive for lupus anticoagulant and negative for anticardiolipin antibodies.
It seems likely that the anticardiolipin antibody and lupus anticoagulant tests will become a routine screening procedure in evaluating women with a history of obstetric complications. The mechanism of fetal loss in patients with antiphospholipid antibodies is unknown, but it has been thought to be similar to the mechanism implicated in the vascular thrombosis related to these antibodies. Currently, it is suggested that the endothelial cell itself, or a membrane linked molecule, is the target antigen.
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